Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Apr;13(4):342.
doi: 10.1007/s11910-013-0342-7.

Phenotypic spectrum of glucose transporter type 1 deficiency syndrome (Glut1 DS)

Affiliations
Review

Phenotypic spectrum of glucose transporter type 1 deficiency syndrome (Glut1 DS)

Toni S Pearson et al. Curr Neurol Neurosci Rep. 2013 Apr.

Abstract

Glut1 deficiency syndrome (Glut1 DS) was originally described in 1991 as a developmental encephalopathy characterized by infantile onset refractory epilepsy, cognitive impairment, and mixed motor abnormalities including spasticity, ataxia, and dystonia. The clinical condition is caused by impaired glucose transport across the blood brain barrier. The past 5 years have seen a dramatic expansion in the range of clinical syndromes that are recognized to occur with Glut1 DS. In particular, there has been greater recognition of milder phenotypes. Absence epilepsy and other idiopathic generalized epilepsy syndromes may occur with seizure onset in childhood or adulthood. A number of patients present predominantly with movement disorders, sometimes without any accompanying seizures. In particular, paroxysmal exertional dyskinesia is now a well-documented clinical feature that occurs in individuals with Glut1 DS. A clue to the diagnosis in patients with paroxysmal symptoms may be the triggering of episodes during fasting or exercise. Intellectual impairment may range from severe to very mild. Awareness of the broad range of potential clinical phenotypes associated with Glut1 DS will facilitate earlier diagnosis of this treatable neurologic condition. The ketogenic diet is the mainstay of treatment and nourishes the starving symptomatic brain during development.

PubMed Disclaimer

References

    1. Ann Neurol. 2005 Jan;57(1):111-8 - PubMed
    1. Ann Neurol. 2010 Jan;67(1):31-40 - PubMed
    1. Dev Med Child Neurol. 2011 Jul;53(7):658-63 - PubMed
    1. Diabetes. 2001 Jun;50(6):1464-71 - PubMed
    1. J Neurophysiol. 2005 May;93(5):2864-72 - PubMed

Publication types

MeSH terms

Supplementary concepts